NovaBay Pharmaceuticals, Inc. Announces Major Amendments to Charter, Massive Increase in Authorized Shares, and Approvals at Special Meeting

Key Points from the SEC Form 8-K Filing

• Second Amended and Restated Certificate of Incorporation Filed and Effective
• Shareholders Approve Significant Corporate Changes at March 12, 2026 Special Meeting
• Authorized Common Shares Increased from 1.5 Billion to 5 Billion
• Approval for Issuance of Hundreds of Millions of New Shares from Private Placements
• Removal of Prohibition on Stockholder Action by Written Consent
• Officer Exculpation Added
• New 2026 Equity Incentive Plan Adopted

Details of the Corporate Actions and Shareholder Approvals

On March 12, 2026, NovaBay Pharmaceuticals, Inc. (“NovaBay” or the “Company”) filed a Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which became effective immediately. The changes were approved first by the Board and then by the shareholders during a Special Meeting held the same day.

Major Amendments to the Certificate of Incorporation

• Removal of Prohibition on Stockholder Action by Written Consent:
  
  The company has removed the previous restriction preventing shareholders from acting by written consent, potentially allowing for faster and more flexible corporate decision-making.
• Officer Exculpation:
  
  Officers are now exculpated from monetary damages to the fullest extent permitted by Delaware law, with some limitations (e.g., breach of loyalty, bad faith, personal benefit, etc.). This aligns officer protections with those typically granted to directors.
• Increase in Authorized Common Shares:
  
  The total number of authorized shares of Common Stock has been increased from 1,500,000,000 to 5,000,000,000 (par value \$0.01 per share). The authorized Preferred Stock remains at 5,000,000 shares.

Shareholder Votes: All Major Proposals Approved

At the Special Meeting, shareholders voted on and approved the following key proposals:

1. Issuance of 837,696,130 Shares:
   
   Approval to issue up to 837,696,130 shares of Common Stock upon exercise of pre-funded warrants issued in a private placement on January 16, 2026.
2. Issuance of 5,405,406 Shares:
   
   Approval to issue up to 5,405,406 shares of Common Stock upon exercise of pre-funded warrants from a private placement on October 16, 2025.
3. Removal of Written Consent Prohibition:
   
   Shareholders approved the removal of the prohibition on stockholder action by written consent, as detailed earlier.
4. Officer Exculpation:
   
   Shareholders approved the amendment providing for officer exculpation from monetary liability under certain circumstances.
5. Increase in Authorized Shares:
   
   Approval to increase authorized Common Stock from 1.5 billion to 5 billion shares.
6. Adoption of 2026 Equity Incentive Plan:
   
   Approval to implement a new equity incentive plan for employees, consultants, and directors.

Since all proposals passed, the proposal to adjourn the meeting to solicit additional proxies was not required.

Potentially Price-Sensitive Implications for Shareholders

• Massive Dilution Potential:
  
  The increase in authorized shares to 5 billion and the approval for the issuance of over 843 million new shares from recent private placements could result in significant dilution for existing shareholders. This is a material event likely to impact share value and market perception.
• Corporate Flexibility:
  
  The ability to act via written consent and the new officer exculpation provisions may make NovaBay more agile in executing strategic actions, mergers, or financings, but may also reduce certain shareholder protections.
• New Equity Incentive Plan:
  
  The adoption of the 2026 Equity Incentive Plan could lead to further dilution depending on the number of equity awards granted in the future.

What Investors Should Watch

• Monitor how and when the newly authorized shares are issued and whether additional capital raises or acquisitions are pursued.
• Review the terms of the private placements and pre-funded warrants for pricing and conversion terms, as these will affect the dilution magnitude.
• Stay alert to additional charter or bylaw amendments, especially those affecting shareholder rights.
• Assess how the expanded equity incentive plan may impact executive compensation and share structure.

Conclusion

These sweeping changes mark a pivotal moment for NovaBay Pharmaceuticals. The potential for significant share dilution and the overhaul of key governance provisions are material events that all investors and stakeholders must carefully consider. Shareholders should closely monitor further company disclosures, particularly regarding the timing and recipients of new share issuances, and the implementation of the new equity incentive plan.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors are encouraged to perform their own due diligence and consult with a qualified financial advisor before making investment decisions. The information is based on the company’s SEC filing as of March 12, 2026, and may be subject to change.

View NovaBay Pharmaceuticals, Inc. Historical chart here